Advanced Accelerator Applications S.A. (NASDAQ:AAAP) today announced its financial results for the third quarter and the first nine months of 2015. Commenting on the third quarter performance, AAA’s CEO Stefano Buono said: “We are entering a new phase at AAA, and the third quarter was a pivotal and exciting time for our company. With the announcement of positive Phase 3 results from the NETTER-1 trial in September, and the subsequent completion of a successful initial public offering in November, we believe we are well positioned to advance the development of our lead drug candidate Lutathera in patients with advanced midgut neuroendocrine tumors. Additionally, we plan to file a New Drug Application (“NDA”) with the U.S Food and Drug Administration and a Marketing Authorization Application (“MAA”) in the European Union for Lutathera by the end of the first quarter of 2016.“
Recent Highlights:
– Reported of an increase in year-over-year sales of approximately 37% for Q3 2015 compared to Q3 2014
– Reported an increase in year-over-year sales of approximately 32% for the first nine months of 2015 compared to the first nine months of 2014
– Completed an Initial Public Offering (“IPO”) and listed on the Nasdaq Global Select Market under the ticker “AAAP”
– Announced positive results from Phase 3 NETTER-1 study, evaluating lead drug candidate Lutathera in patients with advanced midgut neuroendocrine tumors
– Obtained two Marketing Authorizations in France for FCholine and FDopa
– Received FDA Priority Review for Somakit-TATE New Drug Application
– Submitted MA application to EMA for Somakit-TOC